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Setting. A nationwide study in Fiji.Objective. To describe the incidence of congenital rubella syndrome (CRS) and its relationship to
the incidence of notified cases of rubella in Fiji from 1995 to 2010.Design. Descriptive, retrospective review of all recorded congenital
abnormalities associated with live births in Fiji over 16 years. Results. There were 294 infants whomet the criteria for CRS. Of these,
95% were classified as “suspected” cases, 5% were “clinically confirmed,” and none were “laboratory confirmed cases”. There was a
significant linear increase over the study period in the incidence of CRS (odds ratio 1.045 per year, 95% CI 1.019 to 1.071, 𝑃 ≤ 0.001).
There was no significant association between the incidence of CRS and the reported incidence of rubella (𝑃 = 0.3). Conclusion.
There is a rising trend in reports of suspected CRS cases in Fiji.This highlights the need to strengthen surveillance for CRS through
improvements in clinical and laboratory diagnosis to confirmor exclude suspected cases. It is also important to ensure high coverage
of rubella vaccination in Fiji.
1. Introduction
Whilst rubella is usually amild disease in adults and children,
maternal infectionwith rubella, especially early in pregnancy,
can cause severe defects in the developing foetus, resulting
in congenital rubella syndrome (CRS). The constellation of
anomalies of CRS includes ophthalmic, auditory, cardiac, and
craniofacial defects [1].
CRS is common in developing countries, affecting about
110,000 infants annually in these countries [2]. In 2009 there
were 121,344 cases of rubella reported from 167 WHO mem-
ber countries [2]. In addition, 165 cases of CRS were reported
toWHOby 123member countries in the same year [2]. In the
Western PacificRegion, the number of rubella cases increased
12-fold from 5475 in 2000 to 73077 in 2009. With rubella
a growing problem in the Western Pacific Region, there are
concerns that CRS may also be on the rise in this region.
The relationship between the incidence of rubella and the
incidence of CRS has not been clearly shown, although some
studies from resource poor settings, such as Romania, have
shown clusters of children with CRS after rubella outbreaks
[2]. In Fiji, the incidence of rubella has ranged between 1 and
30 cases per 100,000 populationwith outbreaks noted in 1995,
2002, 2006, and 2011 [3].Themost recent rubella outbreak, in
July 2011, has highlighted the need to carry out surveillance
of CRS in Fiji. Vaccination against rubella was introduced in
1975 for females (at 12 years of age), and in 2004 this was
extended to include bothmales and females at primary school
entry [4]. However, a lack of information on the incidence of
CRS in Fiji limits our ability to assess the effectiveness of these
vaccination campaigns.
To address this information gap, this study seeks to (a)
report on the incidence of CRS in Fiji and the relationship
between the incidence of CRS and the incidence of notified
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“Suspected” CRS
Includes any infant less than one year old, presenting with heart disease, suspicion of
deafness, or one or more of the following eye signs: cataract, diminished vision, nystagmus,
squint, microphthalmus, congenital glaucoma, or where the mother has a history of suspected
or confirmed rubella during pregnancy even when the infant shows no signs of CRS.
“Clinically confirmed” CRS
Includes any infant less than one year old who has at least two of the complications listed in
(a) or one in (a) and one in (b) below:
(a) Cataract, congenital glaucoma, congenital heart disease, loss of hearing, pigmentary retinopathy
(b) Purpura, splenomegaly, radiolucent bone disease, jaundice that begins within 24 hours after birth.
“Laboratory confirmed” CRS
Includes any infant less than one year old, with clinically-confirmed CRS who has a positive
blood test for rubella specific IgM or in whom rubella virus is detected in specimens from
pharynx or urine.
CRS: congenital rubella syndrome.
Box 1: WHO diagnostic classification for CRS.
cases of rubella since 1995 and (b) document how CRS
cases are classified (suspected (possible), clinically confirmed
(probable), or laboratory confirmed (definite)) over the
period 1995–2010.
2. Methods
2.1. Design. This was a descriptive study involving a ret-
rospective review of all recorded congenital abnormalities
associated with live births in Fiji over a 16-year period (1995–
2010).
2.2. Setting. Fiji is an island nation located in the South-
West Pacific with a population of approximately 837,271 [5].
It consists of approximately 332 islands covering a total land
area of about 18,333 sqkm [5]. The main sources of revenue
are from tourism and primary industry [5].
The Ministry of Health (MoH) in Fiji provides decen-
tralized health services through a three tier structure of
primary, secondary, and tertiary care. Fiji’s health system
comprises three divisional hospitals, 17 subdivisional hospi-
tals, 78 health centres, and 103 nursing stations [5]. There
is a hierarchical referral mechanism from nursing stations
to health centres to subdivisional and divisional hospitals.
Infants born with congenital defects requiring intervention
are likely to be referred to the paediatric departments in the
three divisional hospitals—Colonial War Memorial (CWM)
Hospital, LautokaHospital, and LabasaHospital. Infants with
newly diagnosed congenital anomalies are routinely admitted
to intensive care wards at these hospitals.
2.3. Sample. The study population included all live births in
Fiji with a congenital anomaly registered between January 1,
1995, and December 31, 2010.
2.4. Data Collection
2.4.1. Data Sources. Between November 2011 and April 2012,
data were sourced from the three divisional hospitals. All
newborn infants with congenital anomalies were identified
from the Congenital Anomalies registers when these registers
were available, and when not available, from a review of
the Neonatal Intensive Care Unit registers. Data on the
number of live births and the annual population numbers
were obtained from MoH Consolidated Monthly Reports
(CMR) for the period 1995–2008 and from the MoH Public
Health Information System (PHIS) for the period 2009-2010.
Data on the annual number of reported cases of rubella were
obtained from the National Notifiable Disease Surveillance
SystemReports for the period 1995–2010.TheCMRandPHIS
records were used to allow calculation of the incidence rates
of CRS and rubella.
2.4.2. Variables. For each recorded case of CRS the follow-
ing data were collected: hospital, date registered, date of
birth, sex, ethnicity, and description of congenital defects.
The presence or absence of specific congenital defects was
recorded, as specified in the WHO diagnostic classification
for CRS [1] and cases were classified as “suspected,” “clinically
confirmed,” or “laboratory confirmed” (see Box 1).
2.4.3. Data Management and Validation. Data was directly
entered into anExcel spreadsheet. Patient noteswere available
for some cases of CRS diagnosed from 2002 onwards. Where
these notes were available, they were reviewed to verify
the diagnosis that had been recorded in the Congenital
Anomalies book or the Neonatal Intensive Care Unit register.
2.5. Analysis and Statistics. The validated dataset was anal-
ysed in Microsoft Excel. Pivot tables were used to tabulate
CRS and rubella cases by year of registration. The incidence
of CRS was expressed per 1000 live births, and the incidence
of rubella was expressed as cases per 100,000 population for
each year.
The association between the incidence of rubella and the
incidence of CRS was estimated by linear regression using
Epi-Info, version 3.5.1.
Journal of Tropical Medicine 3
Table 1: Characteristics of infants with CRS in Fiji, 1995–2010.
Characteristic Number of CRS cases∗ (%)
Total 294
Sex
Males 154 (52)
Females 128 (44)
Not recorded 12 (4)
Ethnicity
I-Taukei (indigenous population) 178 (61)
Fijians of Indian Ethnic Descent 90 (31)
Fijians of Other Ethnic Descent 14 (5)
Not recorded 12 (4)
∗Number of CRS cases includes those suspected, clinically confirmed, and
laboratory confirmed for CRS.
CRS: congenital rubella syndrome.
3. Results
The Congenital Anomalies book was not available for Lau-
toka Hospital and for Labasa Hospital before 2010. Data was
alsomissing for CWMHospital for 1998 and June–December
for 2000.
Based on the available data, a total of 977 babies with
congenital anomalies were recorded between 1995 and 2010
in Fiji and initially 294 of these cases were found to meet
the criteria for CRS. Patient folders were then consulted
to verify the diagnosis and classification. Folders were only
available for 38 (13%) of these 294 cases. In 33 cases the review
confirmed the recorded diagnosis and classification. In three
cases the diagnosis was not changed but the classification
was changed from “suspected” to “clinically confirmed” CRS.
In two cases the diagnosis was changed from CRS to other
congenital anomalies. Thus in total, 294 cases of CRS were
included in the analysis.
CRS cases comprised more males than females and I-
Taukei was the most common ethnic group followed by
Fijians of Indian Ethnic descent (Table 1).
Between 1995 and 2010, there was a significant linear
increase in the incidence of CRS (odds ratio 1.045 per year,
95% CI 1.019 to 1.071, 𝑃 < 0.001), with this incidence ranging
from 0.4 cases per 1000 live births in 1995 to about 1.7 cases
per 1000 live births in 2010 (Figure 1). Whilst the peak in
incidence of rubella and the incidence of CRS coincided in
2002, there was no significant association between incidence
of CRS and rubella (𝑃 = 0.3) (Figure 1).
The majority of CRS cases (𝑛 = 278, 95%) were classified
as “suspected” (Figure 2). The highest annual proportions of
clinically confirmed cases were registered in 1995 and 1996.
Thereafter, the annual proportion of clinically confirmed
cases was consistently less than 20% of total CRS cases.
Therewere no laboratory confirmed cases.Themost common
presentations in babies with CRS were congenital heart
disease (80%) followed by Jaundice (10%).
4. Discussion
This study demonstrates an increasing trend in the incidence
of suspected CRS over the past 16 years. However, very few
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Figure 1: Relationship between incidence of rubella and incidence
of congenital rubella syndrome in Fiji, 1995–2010.
cases were clinically confirmed and there were no laboratory
confirmed cases of CRS.There was no significant relationship
between the incidence of CRS and the incidence of rubella.
4.1. Strengths. This study is based on data for CRS recorded
in all four divisions of Fiji. Hence it includes all reported cases
of CRS and is therefore nationally representative. We have
ensured that the data are comparable among the hospitals
and with international reports by using a standard criteria,
as recommended by WHO, to classify the cases.
The study adhered to STROBE guidelines [6].
4.2. Limitations. Validation of the diagnosis of CRS was
limited in this study.There was a lack of information on clin-
ical and laboratory aspects of the diagnosis in the registers.
Only a small proportion of patient folders were available for
validation purposes. Hence, we were not able to adequately
assess the validity of the registers as a source of information
on the diagnosis of CRS. Furthermore, not all hospitals had a
congenital anomalies book and, where this did not exist, we
could only obtain the diagnostic information by searching the
Neonatal Intensive Care Admission Book. The information
contained in this book was also limited as it did not include
laboratory results or detailed clinical findings.
4.3. Comparison with Previous Studies. The range in inci-
dence of possible CRS recorded in Fiji is similar to that
reported in developing countries during epidemics at about
0.6–2.2 per 1000 live births [7, 8]. This range of incidence
is also similar to that of industrialized countries prior to
vaccination [7, 8].
Whilst there was no significant relationship found
between the incidence of rubella and incidence of CRS in Fiji,
rubella outbreaks leading to increased incidences of CRShave
been documented in other countries such as Panama, Oman,
and Sri Lanka [8].
4.4. What Might Explain the Findings. The majority of the
CRS cases are “suspected” cases in which the clinical finding
was congenital heart disease. Improvements in diagnosis of
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1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Clinically confirmed CRS 3 3 1 0 1 1 0 2 0 1 0 0 1 2 1 0
Suspected CRS 5 13 10 11 17 19 19 26 19 15 15 10 18 28 14 39
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Figure 2: Classification of congenital rubella syndrome (CRS) by year, Fiji, 1995–2010.
congenital heart disease over time could be contributing
to increasing numbers of cases of suspected CRS reported
during this period.
The low numbers of clinically confirmed cases reported
may be due to difficulties in assessment at birth particularly
for features that become more apparent at a later stage of life,
for example, deafness, blindness, and mental retardation.
The lack of a significant relationship between the inci-
dence of CRS and the incidence of rubella may be caused
by underreporting of rubella due to shortcomings with data
recording and management at the hospitals.
4.5. Implications of the Findings. The increasing incidence of
suspected CRS in Fiji demonstrated through this study has
implications for both clinical management and surveillance
purposes.The absence of any laboratory confirmedCRS cases
suggests the need to develop standard operating procedures
and guidelines for confirming diagnosis through serological
tests so that we are able to accurately estimate the burden of
CRS in Fiji. Considering the challenges in documenting the
extent of CRS in the population due to great variation in the
manifestations of CRS in the first year of life and diagnostic
issues related to detecting some of these features, a system
would need to be established for close followup of these
infants inmaternal and child health clinics in order to identify
features of CRS that may not be possible to assess at birth.
This study also suggests the need to monitor adequacy of
rubella prevention, through the current rubella vaccination
programme carried out at primary school entry. WHO
recommends coverage rates to be maintained above 80% to
ensure herd immunity [9]. Low coverage rates may indicate
the need for serological surveys among women of child bear-
ing age. Furthermore, assessment of the sensitivity, specificity,
and predictive value of the different clinical definition of CRS
may need to be carried out [7].
The very small proportion of patient folders obtained for
validation through this study suggests the need to improve
information management and record keeping at health facil-
ities. Ultimately an improvement in surveillance of CRS
would allow evaluation of our disease control efforts towards
elimination of rubella and CRS.
5. Conclusion
There is a rising trend in reports of suspected CRS cases
in Fiji. This highlights the need to strengthen surveillance
for CRS through improvements in clinical and laboratory
diagnosis to confirm or exclude suspected cases. It is also
important to ensure high coverage of rubella vaccination in
Fiji.
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